IR@PKUHSC  > 北京大学第一临床医学院  > 肿瘤化疗科
学科主题临床医学
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma
Zhang, Xiao-tian1; Li, Jian1; Bai, Yu2; Chu, Yu-ping3; Li, Jie1; Li, Yan1; Gong, Ji-fang1; Shen, Lin1
关键词Capecitabine Fluoropyrimidine-platinum Resistant Metastatic Gastric Adenocarcinoma Paclitaxel Second-line Chemotherapy
刊名JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
2013-11-01
DOI10.4103/0973-1482.122512
suppl.2期:7页:S153-S157
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]2ND-LINE CHEMOTHERAPY ; 1ST-LINE THERAPY ; SUPPORTIVE CARE ; CANCER ; TRIAL ; CISPLATIN ; PLUS ; 5-FLUOROURACIL ; SURVIVAL ; S-1
英文摘要

Background: Although randomized trials have shown a survival benefit of second-line chemotherapy (SLC) in metastatic gastric adenocarcinoma (MGA), no standard regimen has yet been established. Paclitaxel acts synergistically with capecitabine. In this phase II study, we evaluated the efficacy and safety of paclitaxel/capecitabine (PX) as an SLC regimen for patients with fluoropyrimidine-resistant MGA.

Materials and Methods: Patients were eligible if the tumor progressed to fluoropyrimidine-based regimens or relapsed within 6 months after completion of therapy with adjuvant fluoropyrimidines. Treatment consisted of paclitaxel (80 mg/m(2), days 1 and 8) and capecitabine (1000 mg/m(2), bid, days 1-14), called PX, every 3 weeks. The primary endpoint was the objective response rate (ORR). Thirty-five patients were required according to the statistical design, and PX combination would be rejected if fewer than five patients responded.

Results: From November 2004 to May 2007, 36 eligible patients were enrolled. Among them, 35 (97.2%) had previously received platinum/fluoropyrimidine as first-line therapy. Response was assessed in 35 patients; 10 partial responses were obtained, resulting in an ORR of 28.5%. The median progression-free survival was 5.0 months, and the median overall survival was 11.1 months. The most frequent grade 3/4 toxicity was neutropenia, observed in 11.1% of the patients.

Conclusions: PX regimen was clearly demonstrated to be active and safe for fluoropyrimidine-platinum-resistant MGA, and further evaluation in future phase III trials is warranted.

语种英语
WOS记录号WOS:000330893900007
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56146
专题北京大学第一临床医学院_肿瘤化疗科
作者单位1.Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Gastrointestinal Oncol, Beijing 100142, Peoples R China
2.Peking Univ, Hosp 1, Dept Med Oncol, Beijing 100142, Peoples R China
3.Capital Med Univ, Beijing Chao Yang Hosp, Dept Med Oncol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Xiao-tian,Li, Jian,Bai, Yu,et al. A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma[J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS,2013,suppl.2(7):S153-S157.
APA Zhang, Xiao-tian.,Li, Jian.,Bai, Yu.,Chu, Yu-ping.,Li, Jie.,...&Shen, Lin.(2013).A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.JOURNAL OF CANCER RESEARCH AND THERAPEUTICS,suppl.2(7),S153-S157.
MLA Zhang, Xiao-tian,et al."A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma".JOURNAL OF CANCER RESEARCH AND THERAPEUTICS suppl.2.7(2013):S153-S157.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Xiao-tian]的文章
[Li, Jian]的文章
[Bai, Yu]的文章
百度学术
百度学术中相似的文章
[Zhang, Xiao-tian]的文章
[Li, Jian]的文章
[Bai, Yu]的文章
必应学术
必应学术中相似的文章
[Zhang, Xiao-tian]的文章
[Li, Jian]的文章
[Bai, Yu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。